ArticleMicrobiology spectrum2025
Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant
Jing Wu, Yuanfei Ji, Weihe Zhang, Siyi Chen, Yao Dong, Xia Yu
Abstract read
In one paragraphArticle in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Jing Wu *National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yuanfei Ji *National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Weihe ZhangNational Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Siyi ChenNational Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yao DongNational Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Xia YuNational Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0002-1400-7321 Funding
Beijing Public Health Experts Project G2023-3-004Outstanding Young Scientific and Technological Workers in Tongzhou District JCQN2023011
6 · The paper itselfAbstract
Multidrug-resistant tuberculosis (MDR-TB) is often associated with poor clinical outcomes. This study evaluated the
Indexed as
Antitubercular AgentsMycobacterium tuberculosisPolycyclic CompoundsTuberculosis, Multidrug-ResistantAnimalsDiterpenesDrug Resistance, Multiple, BacterialDrug SynergismHumansMicrobial Sensitivity TestsThioglycolatesAntitubercular AgentsDiterpeneslefamulinPolycyclic CompoundsThioglycolatesantimicrobial activityintracellular activitylefamulinMycobacterium tuberculosis
Identifiers
PMID41059697
PMCPMC12584698
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390